



Promising, or Wishful Thinking?*
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Valvular aortic stenosis (AS) is a prevalent condition and
one of the most common indications for valve replacement
surgery. Although AS can be congenital in etiology or a
consequence of rheumatic fever, the most common form is
“calcific” AS. Calcific AS is usually seen in patients over the
age of 65 years, and as the population continues to grow
older, the number of patients with AS is almost certain to
rise. Using both noninvasive and invasive techniques, a
number of studies have documented that AS is a progressive
disease, although the rate of progression may vary consid-
erably from patient to patient. At present, no medical
therapy has been proved effective in patients with severe AS.
The management of patients with AS has been reviewed
in a recent update (1). When AS causes symptoms of heart
failure, syncope, or angina, prompt surgical replacement of
the stenotic aortic valve is indicated. Although asymptom-
atic patients with AS have a relatively good prognosis, a
subgroup of patients who lack symptoms at rest will
demonstrate poor exercise tolerance or other worrisome
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features (such as hypotension or ventricular tachycardia)
when they perform careful, physician-supervised exercise
testing. Such patients may also be candidates for valve
replacement surgery. Successful aortic valve replacement
(AVR) surgery markedly improves prognosis in symptom-
atic AS patients, even those with substantial left ventricular
(LV) dysfunction. Except in children with congenital AS,
alternative mechanical approaches to AS (such as percuta-
neous balloon valvuloplasty or aortic decalcification proce-
dures) do not lead to a good long-term outcome. Thus,
many patients with AS will eventually need surgical AVR.
This can be carried out in experienced centers with a
reasonably low operative mortality, even in AS patients with
depressed LV function.
However, operative mortality and morbidity are increased
in older patients with AS, particularly those with comor-
bidities that are not rare in the elderly: coronary artery
disease, cerebrovascular disease, impaired renal function,
and chronic respiratory disorders. Accordingly, a safe and
effective medical therapy that would slow the progression of
AS, and that might thereby alleviate the need for AVR
surgery in some patients, clearly would be very promising
and of considerable clinical interest.
BACKGROUND
For many years, the progression of calcific AS was consid-
ered a “wear and tear” phenomenon—a consequence of
aging coupled with increased hydrodynamic stresses on the
abnormal aortic valve. The concept that “scarring begets
scarring” appeared to explain the observed progressive in-
creases in transvalvular gradient and decreases in aortic valve
orifice area that are seen in AS patients who are followed
longitudinally. In the past decade, however, interesting
epidemiologic (2–4) and histologic (5–7) similarities be-
tween AS and atherosclerosis have been reported. These
conditions are not only more prevalent with increasing age,
but both disorders also demonstrate associations with gen-
der, hyperlipidemia, hypertension, diabetes, and smoking.
Histologic studies of stenotic aortic valve specimens re-
moved at AVR or necropsy demonstrate regions of chronic
inflammation reminiscent of those seen in atherosclerosis,
including lipoprotein deposition, cellular infiltration of
macrophages and T-lymphocytes (6), and calcification (7).
There is clear evidence that progression of coronary athero-
sclerosis can be favorably reduced or even reversed by
medical therapy (8). The intriguing similarities between
atherosclerosis and calcific AS have stimulated a growing
interest in the possibility that medications documented to
be effective in patients with atherosclerotic coronary artery
disease might be used to slow the progression of AS.
CONTRIBUTIONS OF THE CURRENT ARTICLE
In the current issue of the Journal, Bellamy et al. (9) make
several important additions to our understanding of AS
progression. They confirm the earlier observations of other
investigators that measures of AS severity show progressive
increases in transvalvular gradient and decreases in valve
orifice area. Importantly, the study of Bellamy et al. (9) is an
extension of the prospective, population-based Rochester
Epidemiology Project, in which the majority of patients
were studied not because of a change in clinical status, but
rather were re-evaluated systematically during follow-up
even though they remained asymptomatic. Their finding
that, in general, the annualized decrease in calculated aortic
valve area (AVA) was approximately 0.1 cm2 is consistent
with the findings of other authors (10–12).
Bellamy et al. (9) also investigated the relationship
between plasma lipid values and the rate of AS progression.
In patients not receiving lipid-lowering therapy during
follow-up, the authors found that the rate of AS progression
(based on measures of transvalvular velocity, gradient, and
valve orifice area) did not demonstrate a significant relation-
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ship with plasma cholesterol levels (expressed either as total
cholesterol (TC) or low-density lipoprotein cholesterol
[LDL-C] ). Rates of change of AVA were not significantly
different when patients were subdivided according to TC
quartiles. Neither total nor LDL-C values differed between
patients in whom the annualized rate of AS progression
exceeded the median value (“fast progressors”) and those
with progression rates less than the median value (“slower
progressors”). These observations are important because
some previous studies (2,4,13) have reported a positive
association between hypercholesterolemia and the rate of
AS progression, whereas others (14) have not. The majority
of these earlier studies were retrospective analyses, however,
and potentially subject to referral bias. These shortcomings
were avoided in the prospective, population-based study of
Bellamy et al. (9).
In nearly 25% (38 of 156) of the patients studied by
Bellamy et al. (9), treatment with a 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG CoA) reductase inhibitor
(“statin”) agent had been prescribed by the patient’s treating
physician. Statin treatment was not randomized, but based
on clinical indications; statin-treated patients usually had
not only documented hypercholesterolemia, but also docu-
mented coronary artery disease or significant coronary risk
factors. Notably, patients treated with a statin agent dem-
onstrated a significantly lower rate of AS progression during
systematic follow-up (annualized mean decrease in AVA
0.04 cm2) compared with untreated patients (annualized
mean decrease 0.09 cm2). Statin usage remained a signifi-
cant independent predictor of the rate of AS progression
even after adjustment for age, gender, and baseline AVA.
Interestingly, the magnitude of decrease in TC and LDL-C
values during statin therapy did not show a significant
correlation with the rate of AS progression. Similar findings
were noted in the 108 patients (nearly 70% of the study
population) in whom repeated evaluations were performed
systematically and not because of some clinical change in the
study patients.
The current findings of Bellamy et al. (9) are remarkably
similar to those of the earlier retrospective study reported by
Novaro et al. (15). That group of investigators also noted
that statin usage was an independent predictor of the rate of
AS progression (with annualized mean decreases in AVA of
0.06 cm2 in statin-treated AS patients, compared with
0.11 cm2 in untreated AS patients), and that the relation-
ship between the decrease in LDL-C values and the rate of
change in AVA was not significant. The retrospective study
of Aronow et al. (13) also noted that compared with
untreated patients, statin-treated AS patients demonstrated
a slower rate of progression during follow-up.
Accordingly, the prospective population-based study of
Bellamy et al. (9) confirms earlier and largely retrospective
reports that: 1) AS is a progressive disorder; 2) statin
therapy is associated with a significant reduction in the
annualized rate of AS progression; and 3) the effect of statin
therapy on the rate of AS progression cannot be explained
simply by changes in plasma lipids.
SHORTCOMINGS OF THE CURRENT STUDY
As with all studies, it is possible, in retrospect, to identify
some shortcomings. In the study of Bellamy et al. (9), statin
treatment was not assigned randomly to AS patients, but
rather was (or was not) prescribed by the patient’s treating
physician, apparently based on accepted clinical indications.
Five different statin agents were prescribed, and although
the doses of each individual statin agent were variable, the
mean doses generally were relatively low. In addition,
patients included in this study were elderly (the mean age of
study patients was 76 years and statin-treated patients
were on average 73 years old at the time of study enroll-
ment). Study patients also had relatively established AS,
with an average mean gradient of 22 mm Hg and a mean
AVA approximately 1.2 cm2. Indeed, the criteria for inclu-
sion (baseline mean gradient at least 10 mm Hg and AVA
no more than 2 cm2) would by definition exclude patients
with “aortic sclerosis,” those with mild leaflet thickening but
only a trivial transvalvular gradient. Hence, although in-
triguing, the findings of Bellamy et al. (9) do not definitively
prove that statin therapy is effective in reducing the rate of
AS progression.
AREAS FOR FUTURE INVESTIGATION
Observations by a number of investigators over the past
decade have demonstrated convincingly that aortic valve
calcification and stenosis is not just a disease of aging, and
that AS does not progress purely because of increased
hydrodynamic stresses on the abnormal valve leaflets.
Rather, progression of AS has a fascinating histologic and
biochemical basis that suggests an important role of tissue
injury, inflammation, and remodeling. A better understand-
ing of the pathobiology of this process may offer insights
into appropriate therapy.
Because epidemiologic studies have indicated an associ-
ation between hypercholesterolemia and calcific AS, and
because histologic assessment of valve tissue from patients
with AS demonstrates lipoprotein accumulation and oxida-
tion in diseased valves, it seems logical to postulate that
lipid-lowering therapy might slow the rate of AS progres-
sion. The studies of Aronow et al. (13), Novaro et al. (15),
and Bellamy et al. (9) all demonstrate a significant decline in
the rate of AS progression in patients treated with statin
agents, albeit in a nonrandomized manner. I certainly agree
with the concluding recommendation of all of these inves-
tigators: a large randomized clinical trial of HMG CoA
reductase inhibitor therapy in patients with AS is warranted.
The observation that the decrease in AS progression in
statin-treated patients is out of proportion to the more
modest decreases in plasma cholesterol measures raises the
intriguing possibility that the effect of statins on AS
progression might be based on mechanisms different from
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simply lowering LDL-C and TC. For years, investigators
have recognized that atherosclerosis has an important in-
flammatory component (16). Leukocyte adherence to re-
gions of lipid accumulation, conversion of monocytes to
macrophages, and formation of foam cells leads initially to
fatty streaks, and eventually to local fibrosis and remodeling.
Although the progression of atherosclerosis is slowed by
treatment with statin agents, statin therapy also has been
shown to reduce adverse ischemic events even in patients
with coronary artery disease who are not hypercholester-
olemic (17).
This intriguing observation appears to have a biochemical
basis. HMG-CoA reductase inhibition blocks the choles-
terol synthetic pathway at the level of conversion of hy-
droxymethylglutaryl coenzyme A to mevalonate (18). Sub-
sequent lipid moieties include not only cholesterol, but also
intermediates such as geranyl pyrophosphate and farnesyl
pyrophosphate, nonsterol isoprenoids that appear to play an
important role in the control of cell growth, proliferation,
and secretion. It is postulated that by blocking the choles-
terol synthetic pathway and reducing production of these
nonsterol isoprenoids, statin agents may alter cellular be-
havior. Indeed, recent studies have demonstrated that
HMG-CoA reductase inhibitors reduce secretion of matrix
metalloproteins by macrophages (19) and cause an improve-
ment in endothelial function by attenuating superoxide
anion formation (20). Because matrix metalloproteins lead
to degradation of extracellular matrix, and because endothe-
lial dysfunction plays an important role in atherogenesis,
statin agents may exert an anti-atherogenic effect through
their effects on macrophage behavior.
Whether similar processes play a role in the evolution of
the histologic and functional abnormalities in AS is only
speculative. Clearly, AS and atherosclerosis have not only
notable similarities, but important differences (21). None-
theless, several observations are intriguing. As in atheroscle-
rosis, chronic inflammatory cells are also present in valve
leaflets from patients with aortic sclerosis and AS (5,6).
Serum levels of C-reactive protein, a sensitive marker of
systemic inflammation, are also elevated in patients with
established AS (22). Pravastatin was shown recently to
lower the median level of C-reactive protein in a prospec-
tive, randomized community-based double-blind trial (23).
Thus, the beneficial effect of statins that have been seen in
patients with AS could be due to their anti-inflammatory
properties.
Because valve specimens in patients with AS demonstrate
not only lipid accumulation but also other histologic abnor-
malities, additional therapeutic approaches may deserve
consideration. In AS, activated macrophages produce os-
teopontin, a protein that is involved in tissue calcification
(24). Even early lesions of AS show areas of microscopic
mineralization in association with lipid deposition and
leaflet thickening (5). In patients with more advanced
disease (7), dystrophic calcification, microfractures, and
ossification can be seen. It is interesting to note that statin
agents have been associated with a decreased risk of frac-
tures (25), and with reduced rates of aortic valve calcium
deposition as detected using electron beam computed
tomography (26). These observations raise the possibility
that drugs that alter calcium metabolism and ossification
might also be of therapeutic value in patients with AS.
Additional research is needed to define optimal treat-
ment. Is one statin agent more effective than another, or is
there a “class effect”? What is the optimal dosage for slowing
AS progression? Are statin agents effective alone, or would
their efficacy be enhanced by adjunctive therapy with other
anti-inflammatory agents or drugs that alter calcium metab-
olism? In the spectrum of AS, from valve sclerosis to critical
stenosis, when should therapy be started? Are the beneficial
effects of medical therapy restricted to patients with estab-
lished mild-moderate AS, or would they slow (or perhaps
even prevent) progression if started in patients with aortic
sclerosis before they developed hemodynamic obstruction to
LV emptying? Does medical treatment of AS patients result
in measurable differences in outcome, such as delayed onset
of symptoms, reduced need for valve replacement surgery, or
improved survival?
Even though a prospective, randomized (and presumably
multicenter) clinical of statin therapy in patients with AS
would appear to be well warranted, I can imagine potential
problems in patient recruitment and randomization. Pa-
tients with AS frequently also manifest hypercholesterol-
emia, hypertension, and other risk factors for coronary
artery disease, which might make it difficult to assign them
randomly to treatment with a placebo rather than a statin
agent.
In conclusion, the cellular and molecular bases for the
development and progression of AS, and the findings of
studies such as that of Bellamy et al. (9), appear to offer the
promise that a safe and effective medical therapy for AS is
not just wishful thinking. Notwithstanding potential prac-
tical difficulties that might be inherent in conducting a large,
randomized prospective trial of medical treatment in pa-
tients with AS, this condition is too prevalent, and its
consequences too important, to ignore.
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